Literature DB >> 11483746

Antibody-directed targeting of retroviral vectors via cell surface antigens.

K Morizono1, G Bristol, Y M Xie , S K Kung, I S Chen.   

Abstract

Targeted stable transduction of specific cells is a highly desirable goal for gene therapy applications. We report an efficient and broadly applicable approach for targeting retroviral vectors to specific cells. We find that the envelope of the alphavirus Sindbis virus can pseudotype human immunodeficiency virus type 1- and murine leukemia virus-based retroviral vectors. When modified to contain the Fc-binding domain of protein A, this envelope gives a significant enhancement in specificity in combination with antibodies specific for HLA and CD4 relative to that without antibody. Unlike previous targeting strategies for retroviral transduction, the virus titers are relatively high and stable and can be further increased by ultracentrifugation. This study provides proof of principle for a targeting strategy that would be generally useful for many gene therapy applications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11483746      PMCID: PMC115045          DOI: 10.1128/jvi.75.17.8016-8020.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Low-pH-dependent fusion of Sindbis virus with receptor-free cholesterol- and sphingolipid-containing liposomes.

Authors:  J M Smit; R Bittman; J Wilschut
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  A versatile and potentially general approach to the targeting of specific cell types by retroviruses: application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses.

Authors:  P Roux; P Jeanteur; M Piechaczyk
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

3.  In vivo cell type-specific gene delivery with retroviral vectors that display single chain antibodies.

Authors:  A Jiang; R Dornburg
Journal:  Gene Ther       Date:  1999-12       Impact factor: 5.250

4.  A CD4 domain important for HIV-mediated syncytium formation lies outside the virus binding site.

Authors:  D Camerini; B Seed
Journal:  Cell       Date:  1990-03-09       Impact factor: 41.582

5.  Production of infectious RNA transcripts from Sindbis virus cDNA clones: mapping of lethal mutations, rescue of a temperature-sensitive marker, and in vitro mutagenesis to generate defined mutants.

Authors:  C M Rice; R Levis; J H Strauss; H V Huang
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

6.  An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication.

Authors:  D S An; K Morizono; Q X Li; S H Mao; S Lu; I S Chen
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

7.  Retrovirus targeting by tropism restriction to melanoma cells.

Authors:  F Martin; S Neil; J Kupsch; M Maurice; F Cosset; M Collins
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

8.  A murine leukemia virus (MuLV) long terminal repeat derived from rhesus macaques in the context of a lentivirus vector and MuLV gag sequence results in high-level gene expression in human T lymphocytes.

Authors:  S K Kung; D S An; I S Chen
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

9.  Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors.

Authors:  S Valsesia-Wittmann; A Drynda; G Deléage; M Aumailley; J M Heard; O Danos; G Verdier; F L Cosset
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

10.  A gene fusion system for generating antibodies against short peptides.

Authors:  B Löwenadler; B Jansson; S Paleus; E Holmgren; B Nilsson; T Moks; G Palm; S Josephson; L Philipson; M Uhlén
Journal:  Gene       Date:  1987       Impact factor: 3.688

View more
  61 in total

Review 1.  Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.

Authors:  Cecilia Frecha; Camille Lévy; François-Loïc Cosset; Els Verhoeyen
Journal:  Mol Ther       Date:  2010-08-24       Impact factor: 11.454

2.  Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo.

Authors:  Pong-Yu Huang; Jih-Huong Guo; Lih-Hwa Hwang
Journal:  Mol Ther       Date:  2011-11-08       Impact factor: 11.454

Review 3.  Altering the tropism of lentiviral vectors through pseudotyping.

Authors:  James Cronin; Xian-Yang Zhang; Jakob Reiser
Journal:  Curr Gene Ther       Date:  2005-08       Impact factor: 4.391

4.  Targeting lentiviral vectors to specific cell types in vivo.

Authors:  Lili Yang; Leslie Bailey; David Baltimore; Pin Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

5.  Efficient functional pseudotyping of oncoretroviral and lentiviral vectors by Venezuelan equine encephalitis virus envelope proteins.

Authors:  Andrey A Kolokoltsov; Scott C Weaver; Robert A Davey
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Retargeting vesicular stomatitis virus glycoprotein pseudotyped lentiviral vectors with enhanced stability by in situ synthesized polymer shell.

Authors:  Min Liang; Ming Yan; Yunfeng Lu; Irvin S Y Chen
Journal:  Hum Gene Ther Methods       Date:  2013-02       Impact factor: 2.396

7.  Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter.

Authors:  Lai Sum Leoh; Kouki Morizono; Kathleen M Kershaw; Irvin S Y Chen; Manuel L Penichet; Tracy R Daniels-Wells
Journal:  J Gene Med       Date:  2014 Jan-Feb       Impact factor: 4.565

Review 8.  Library screening and receptor-directed targeting of gammaretroviral vectors.

Authors:  Peter M Mazari; Monica J Roth
Journal:  Future Microbiol       Date:  2013-01       Impact factor: 3.165

Review 9.  Lentiviral vectors for immune cells targeting.

Authors:  Steven Froelich; April Tai; Pin Wang
Journal:  Immunopharmacol Immunotoxicol       Date:  2010-06       Impact factor: 2.730

Review 10.  RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?

Authors:  Sandesh Subramanya; Sang-Soo Kim; N Manjunath; Premlata Shankar
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.